247 related articles for article (PubMed ID: 22338574)
1. Platelets in atherothrombosis--diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases.
Bigalke B; Schuster A; Sopova K; Wurster T; Stellos K
Curr Vasc Pharmacol; 2012 Sep; 10(5):589-96. PubMed ID: 22338574
[TBL] [Abstract][Full Text] [Related]
2. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
[TBL] [Abstract][Full Text] [Related]
3. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
4. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
Drouet L; Bal dit Sollier C; Henry P
Drugs; 2010 Nov; 70 Suppl 1():9-14. PubMed ID: 20977287
[TBL] [Abstract][Full Text] [Related]
5. Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
Alenazy FO; Harbi MH; Kavanagh DP; Price J; Brady P; Hargreaves O; Harrison P; Slater A; Tiwari A; Nicolson PLR; Connolly DL; Kirchhof P; Kalia N; Jandrot-Perrus M; Mangin PH; Watson SP; Thomas MR
J Thromb Haemost; 2023 Nov; 21(11):3236-3251. PubMed ID: 37541591
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein VI - novel target in antiplatelet medication.
Borst O; Gawaz M
Pharmacol Ther; 2021 Jan; 217():107630. PubMed ID: 32681846
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet drugs in cardiological practice: established strategies and new developments.
Krötz F; Sohn HY; Klauss V
Vasc Health Risk Manag; 2008; 4(3):637-45. PubMed ID: 18827913
[TBL] [Abstract][Full Text] [Related]
8. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of receptor shedding-platelet GPVI as an emerging diagnostic and therapeutic tool.
Chatterjee M; Gawaz M
Platelets; 2017 Jun; 28(4):362-371. PubMed ID: 27753514
[TBL] [Abstract][Full Text] [Related]
10. Role of antiplatelet drugs in the prevention of cardiovascular events.
Tendera M; Wojakowski W
Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
Lam S; Tran T
Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
[TBL] [Abstract][Full Text] [Related]
12. Is a variability of platelet inhibitory effect of anti-platelet agents important for predicting new lesion in atherothrombotic stroke?
Jung JM; Park JW; Kim SU; Kwon DY; Park MH
Int J Stroke; 2018 Aug; 13(6):NP14-NP15. PubMed ID: 29676226
[No Abstract] [Full Text] [Related]
13. Platelet and soluble glycoprotein VI - novel applications in diagnosis and therapy.
Bigalke B; Elvers M; Schönberger T; Gawaz M
Curr Drug Targets; 2011 Nov; 12(12):1821-30. PubMed ID: 21718237
[TBL] [Abstract][Full Text] [Related]
14. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
[TBL] [Abstract][Full Text] [Related]
15. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Moon JY; Franchi F; Rollini F; Angiolillo DJ
J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
[TBL] [Abstract][Full Text] [Related]
16. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
17. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
Wadowski PP; Eichelberger B; Kopp CW; Pultar J; Seidinger D; Koppensteiner R; Lang IM; Panzer S; Gremmel T
J Cardiovasc Transl Res; 2017 Aug; 10(4):359-367. PubMed ID: 28425039
[TBL] [Abstract][Full Text] [Related]
18. Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke.
Induruwa I; Jung SM; Warburton EA
Int J Stroke; 2016 Aug; 11(6):618-25. PubMed ID: 27312676
[TBL] [Abstract][Full Text] [Related]
19. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
[TBL] [Abstract][Full Text] [Related]
20. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
